Combination therapy aims to outsmart tough lymphoma

NCT ID NCT07673367

Recruiting now Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Aug 06, 2026 · Updated 5 times

Summary

This phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a patient's own immune cells, modified to attack the lymphoma. The study enrolls about 25 adults and will track how long the cancer stays under control after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nemtabrutinib and brexucabtagene autoleucel (CAR T-cell therapy)
What this could lead to: If successful, this combination could offer a more effective treatment option for people with mantle cell lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is a small, early-phase trial (25 participants), so results may not apply broadly. CAR T-cell therapy carries risks of severe side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MANTLE CELL LYMPHOMA REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.